OncoMatch/Clinical Trials/NCT06758544
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
Is NCT06758544 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Oncolytic virus VRT106 and Chemotherapy for pancreatic cancer.
Treatment: Oncolytic virus VRT106 · Chemotherapy — This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: oncolytic virus
Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer
Cannot have received: systemic therapy
Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer
Lab requirements
Blood counts
no serious abnormalities
Kidney function
no serious abnormalities
Liver function
no serious abnormalities
Cardiac function
no serious abnormalities
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06758544 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages